132.39
前日終値:
$130.97
開ける:
$132.24
24時間の取引高:
1.42M
Relative Volume:
0.94
時価総額:
$279.66B
収益:
$53.40B
当期純損益:
$13.68B
株価収益率:
19.22
EPS:
6.8864
ネットキャッシュフロー:
$16.89B
1週間 パフォーマンス:
+7.07%
1か月 パフォーマンス:
+3.24%
6か月 パフォーマンス:
+17.93%
1年 パフォーマンス:
+16.37%
Novartis Ag Adr Stock (NVS) Company Profile
NVS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
NVS
Novartis Ag Adr
|
132.39 | 253.54B | 53.40B | 13.68B | 16.89B | 6.8864 |
![]()
LLY
Lilly Eli Co
|
839.87 | 734.96B | 53.26B | 13.80B | -50.20M | 15.08 |
![]()
JNJ
Johnson Johnson
|
188.64 | 447.90B | 90.62B | 22.66B | 18.18B | 9.35 |
![]()
ABBV
Abbvie Inc
|
233.91 | 417.90B | 58.33B | 3.73B | 18.24B | 2.1013 |
![]()
MRK
Merck Co Inc
|
89.19 | 223.58B | 63.43B | 16.42B | 14.72B | 6.4861 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-09-12 | ダウングレード | Goldman | Neutral → Sell |
2025-08-08 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
2025-02-13 | ダウングレード | UBS | Buy → Neutral |
2025-02-12 | 開始されました | Morgan Stanley | Underweight |
2025-02-04 | アップグレード | Deutsche Bank | Hold → Buy |
2024-12-04 | ダウングレード | HSBC Securities | Hold → Reduce |
2024-09-11 | ダウングレード | BofA Securities | Buy → Neutral |
2024-09-05 | ダウングレード | Goldman | Buy → Neutral |
2024-09-03 | ダウングレード | Jefferies | Buy → Hold |
2024-07-19 | ダウングレード | Deutsche Bank | Buy → Hold |
2024-05-30 | 開始されました | Goldman | Buy |
2024-02-23 | 開始されました | BMO Capital Markets | Market Perform |
2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
2024-01-16 | 再開されました | UBS | Buy |
2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
2023-09-25 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
2023-07-14 | 開始されました | HSBC Securities | Buy |
2023-04-26 | アップグレード | Deutsche Bank | Hold → Buy |
2023-03-27 | アップグレード | Deutsche Bank | Sell → Hold |
2023-01-26 | ダウングレード | Citigroup | Buy → Neutral |
2022-12-05 | アップグレード | Stifel | Hold → Buy |
2022-09-15 | ダウングレード | Credit Suisse | Neutral → Underperform |
2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
2022-05-09 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
2022-01-10 | 再開されました | Citigroup | Buy |
2021-12-14 | ダウングレード | Redburn | Buy → Neutral |
2021-12-06 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
2021-12-03 | ダウングレード | Bryan Garnier | Buy → Neutral |
2021-09-20 | ダウングレード | Deutsche Bank | Hold → Sell |
2021-03-22 | 開始されました | Bernstein | Mkt Perform |
2021-03-10 | ダウングレード | Argus | Buy → Hold |
2021-02-01 | ダウングレード | Cowen | Outperform → Market Perform |
2021-01-15 | 開始されました | Deutsche Bank | Buy |
2020-09-29 | 開始されました | Berenberg | Buy |
2020-09-10 | アップグレード | UBS | Neutral → Buy |
2020-09-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-06-15 | アップグレード | Citigroup | Neutral → Buy |
2020-03-10 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
2020-02-25 | ダウングレード | Guggenheim | Buy → Neutral |
2019-04-25 | アップグレード | Guggenheim | Neutral → Buy |
2019-04-25 | アップグレード | Liberum | Hold → Buy |
2019-04-10 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
2019-01-02 | ダウングレード | JP Morgan | Neutral → Underweight |
2018-12-11 | 再開されました | Jefferies | Buy |
2018-10-09 | 開始されました | Guggenheim | Neutral |
2018-09-10 | アップグレード | BofA/Merrill | Underperform → Buy |
2018-05-29 | ダウングレード | HSBC Securities | Buy → Hold |
2018-05-25 | アップグレード | Credit Suisse | Underperform → Neutral |
2018-01-25 | 繰り返されました | Leerink Partners | Outperform |
2017-12-06 | ダウングレード | BofA/Merrill | Neutral → Underperform |
2017-07-26 | アップグレード | Morgan Stanley | Underweight → Overweight |
2017-07-05 | ダウングレード | Credit Suisse | Neutral → Underperform |
2017-03-09 | 開始されました | Liberum | Buy |
すべてを表示
Novartis Ag Adr (NVS) 最新ニュース
2 Surefire Dividend Stocks to Buy for the Long Haul - The Globe and Mail
Atrial Fibrillation Clinical Trials & Pipeline Overview: Insights into 12+ Leading Companies and 15+ Novel Treatments | DelveInsight - GlobeNewswire Inc.
Trump's New Tariff Barrage Targets Drugs, Trucks, Cabinets: President Says Move Will Protect Manufacturers From 'Unfair Outside Competition' - Sahm
UBS Reaffirms Their Hold Rating on Novartis AG (NOVN) - The Globe and Mail
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream - The Globe and Mail
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments - Sahm
UBS Sticks to Their Hold Rating for Novartis AG (NOVN) - The Globe and Mail
Goldman Sachs Downgrades Novartis (NVS) to Sell Over Risk Concer - GuruFocus
Novartis cut to Sell at Goldman Sachs on near-term risks (NVS:NYSE) - Seeking Alpha
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer - The Globe and Mail
Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver - sharewise.com
Novartis strikes $1.4bn deal for Tourmaline Bio - Proactive financial news
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) - Novartis
Palantir Deepens Industry Ties As Lear And Lumen Embrace Its AI Platforms - Sahm
Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity? - The Globe and Mail
Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.
Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases - Ariva
Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook - Sahm
Drug Delivery Devices Market To Grow At 7.90% CAGR Through 2030, Driven By FDA Approvals And Pipeline Advances By Pfizer, J&J, Novartis, Medtronic, And Becton Dickinson Through 2030 Delveinsight - Menafn
Will EXEL's Share Repurchase Program Boost Value for Investors? - The Globe and Mail
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm - sharewise.com
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease - Novartis
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease - Ariva
What’s Next for Pharma Stocks After Trump’s Drug Price Ultimatum? - Morningstar
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up - The Globe and Mail
Sustainable dividends from European stocks poised to benefit from the tariff wars - The Globe and Mail
Novartis Ag Adr (NVS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):